Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Metabolic Dysfunction-Associated Steatohepatitis

Metabolic Dysfunction-Associated Steatohepatitis

Part of Metabolic Dysfunction-Associated Steatotic Liver Disease

Subtypes of Metabolic Dysfunction-Associated Steatohepatitis

Metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis 1 Metabolic dysfunction-associated steatohepatitis cirrhosis 1 Non-cirrhotic metabolic dysfunction-associated steatohepatitis 1

22 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Metabolic Dysfunction-Associated Steatohepatitis

60 trials tracked for Metabolic Dysfunction-Associated Steatohepatitis: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 991 citations.

60Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 2 Phase 3 2 Phase 2 45 Phase 1 3 Other / NA 8
  1. Phase 4 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed · 991 cited
  2. Phase 4 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed · 311 cited
  3. Phase 3 Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Completed
  4. Phase 3 Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH Completed
  5. Phase 2 Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) Completed
  6. Phase 2 Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy Completed
Show 44 more trials
  1. Phase 2 Pentoxifylline in Patients With Nonalcoholic Steatohepatitis Completed
  2. Phase 2 A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases Completed
  3. Phase 2 A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus Completed
  4. Phase 2 Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis Completed
  5. Phase 2 Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis Completed
  6. Phase 2 Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) Completed
  7. Phase 2 Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) Completed
  8. Phase 2 A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) Completed
  9. Phase 2 Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis Completed
  10. Phase 2 Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Completed
  11. Phase 2 A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH Completed
  12. Phase 2 Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects Completed
  13. Phase 2 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis Completed
  14. Phase 2 A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) Completed
  15. Phase 2 Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis Completed
  16. Phase 2 BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH Completed
  17. Phase 2 Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Completed
  18. Phase 2 A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) Completed
  19. Phase 2 Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis Completed
  20. Phase 2 CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy Completed
  21. Phase 2 A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH Completed
  22. Phase 2 Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis Completed
  23. Phase 2 Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD) Completed
  24. Phase 2 Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) Completed
  25. Phase 2 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis Completed
  26. Phase 2 Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis Completed
  27. Phase 2 A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH Completed
  28. Phase 2 An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis Completed
  29. Phase 2 Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. Completed
  30. Phase 2 Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension Completed
  31. Phase 2 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis Completed
  32. Phase 2 Vitamin E Dosing Study Completed
  33. Phase 2 Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis Completed
  34. Phase 2 Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease Completed
  35. Phase 2 A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Completed
  36. Phase 2 Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) Completed
  37. Phase 2 JKB-121 for the Treatment of Nonalcoholic Steatohepatitis Completed
  38. Phase 2 Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH) Completed
  39. Phase 2 A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) Completed
  40. Phase 2 A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage Completed
  41. Phase 2 Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH Completed
  42. Phase 2 Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis Completed
  43. Phase 2 A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH Completed
  44. Phase 1 A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) Completed

Showing the 50 most-cited and recently-updated of 60 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Proposed pathway for systematic MASLD/MASH assessment in type 2 diabetes
Diabetes & Endocrinology Sys. Review
Proposed pathway for systematic MASLD/MASH assessment in type 2 diabetes New Pathway Proposed to Manage Liver Disease in Diabetes Patients
This narrative review proposes a structured, risk-adapted outpatient pathway for MASLD/MASH assessment in patients with type 2 diabetes, sta…
A new proposed management plan aims to help people with type 2 diabetes identify and assess liver conditions more systematically.
Frontiers Jul 30, 2026
Subcutaneous semaglutide more than doubles the likelihood of NASH resolution without fibrosis progression
Gastroenterology Meta-analysis
Subcutaneous semaglutide more than doubles the likelihood of NASH resolution without fibrosis progression Semaglutide shows promise for treating fatty liver disease and NASH
This meta-analysis of randomized controlled trials evaluated subcutaneous semaglutide in adults with NAFLD or NASH. The analysis found signi…
A new analysis shows that semaglutide can help resolve liver inflammation and improve metabolic health in people with fatty liver disease.
NEJM Jul 26, 2026
Immune crosstalk between innate and adaptive compartments drives inflammatory mechanisms in MASLD and MASH progression
Gastroenterology Sys. Review
Immune crosstalk between innate and adaptive compartments drives inflammatory mechanisms in MASLD and MASH progression Immune system crosstalk drives fatty liver disease progression
This systematic review examines the role of immune system interactions in metabolic dysfunction-associated steatotic liver disease (MASLD) a…
A new review reveals that immune cells talking to each other may be what pushes fatty liver disease toward severe liver damage.
Frontiers Jun 30, 2026
Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis
Diabetes & Endocrinology Meta-analysis
Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis New analysis shows SGLT2 inhibitors may help liver scarring improve in adults with fatty liver disease
A network meta-analysis of 34 trials found FGF21 analogs and SGLT2 inhibitors ranked highest for improving liver fibrosis in MASH, with GLP-…
A large review of trials found SGLT2 inhibitors ranked highest for reducing liver scarring. These drugs also showed good safety and balanced…
Frontiers Jun 4, 2026
Narrative review explores immunometabolic networks in MASH and MASLD
Nutrition & Obesity Medicine Sys. Review
Narrative review explores immunometabolic networks in MASH and MASLD Future treatments for fatty liver disease may use personalized networks to guide care
This narrative review discusses metabolic dysfunction-associated steatohepatitis (MASH) and steatotic liver disease (MASLD), focusing on imm…
New ideas for treating fatty liver disease focus on personalized networks and multi-target approaches to guide future drug development.
Frontiers May 27, 2026
Narrative review explores macrophage reprogramming for liver fibrosis and MASH
Oncology Sys. Review
Narrative review explores macrophage reprogramming for liver fibrosis and MASH Scientists explore new ways to reprogram liver cells to heal damaged tissue and stop scarring
This narrative review summarizes macrophage reprogramming strategies for liver fibrosis and MASH. Approaches include gene modulation, pharma…
A recent review looks at fresh methods to change how liver immune cells behave. These changes could help heal liver scarring and improve hea…
Frontiers May 17, 2026
Review of triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease
Drug Pipeline Sys. Review
Review of triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease New Hope for Fatty Liver Disease Targets Hidden Triglyceride Problem
This narrative review synthesizes evidence on triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease. …
• Lowering triglycerides may directly heal fatty liver damage • Helps millions with metabolic syndrome and stubborn liver fat • Most treatme…
Frontiers May 12, 2026
Network meta-analysis of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis
Gastroenterology Meta-analysis
Network meta-analysis of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis New therapies show promise for liver disease without cirrhosis
This network meta-analysis of 12,787 adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis from phase 2-3 trials evalua…
Treatments targeting metabolism and insulin sensitivity helped more people with early liver disease than placebo, based on a large review of…
May 10, 2026
Meta-analysis of placebo responses in metabolic dysfunction-associated steatohepatitis trials reveals modest natural resolution rates and low progression risk
Gastroenterology Meta-analysis
Meta-analysis of placebo responses in metabolic dysfunction-associated steatohepatitis trials reveals modest natural resolution rates and low progression risk New meta-analysis shows how many patients improve on placebo for MASH
This systematic review and meta-analysis examined placebo outcomes in patients with metabolic dysfunction-associated steatohepatitis.
This analysis of 6,880 patients reveals natural improvement rates in metabolic dysfunction-associated steatohepatitis when no active drug is…
May 1, 2026
Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity
Diabetes & Endocrinology Meta-analysis
Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity Weight-loss drugs and surgery may clear fatty liver disease in adults with high BMI
This systematic review and network meta-analysis evaluates interventions for metabolic dysfunction-associated steatotic liver disease and st…
A new analysis suggests tirzepatide, semaglutide, and surgery might help resolve fatty liver disease without worsening scarring in adults wi…
May 1, 2026
Systematic review and meta-analysis evaluates ML and DL models for diagnosing MASH and fibrosis
Gastroenterology Meta-analysis
Systematic review and meta-analysis evaluates ML and DL models for diagnosing MASH and fibrosis AI models help doctors spot liver disease with high accuracy
This systematic review and meta-analysis of 106 studies assessed machine learning (ML) and deep learning (DL) models for diagnosing metaboli…
New computer tools can diagnose fatty liver disease and scarring with impressive accuracy. This review analyzed data from many studies to se…
May 1, 2026
Meta-analysis compares FAST and MAST scores for MASH with significant fibrosis diagnosis
Rheumatology Meta-analysis
Meta-analysis compares FAST and MAST scores for MASH with significant fibrosis diagnosis New Scans May Spot Dangerous Liver Disease Without a Biopsy
This meta-analysis of four studies evaluated FibroScan-AST (FAST) and MRI-AST (MAST) scores versus liver biopsy for diagnosing metabolic…
These new scan-based scores could help doctors find dangerous liver scarring sooner, without the need for a painful needle biopsy.
Frontiers Apr 23, 2026

Research across Metabolic Dysfunction-Associated Steatotic Liver Disease

Related studies from across the Metabolic Dysfunction-Associated Steatotic Liver Disease family.

Four specific miRNAs in extracellular vesicles satisfy high-tier causality for metabolic and inflammatory regulation
Hematology Sys. Review
Four specific miRNAs in extracellular vesicles satisfy high-tier causality for metabolic and inflammatory regulation Extracellular Vesicles Show Potential for Managing Metabolic Health Conditions
This systematic review evaluates the role of extracellular vesicles (EVs) in managing obesity, type 2 diabetes, MASLD, and atherosclerosis. …
New research identifies specific molecules within extracellular vesicles that may play a role in managing obesity, diabetes, and liver disea…
Frontiers Jul 29, 2026
Novel pharmacotherapies like resmetirom and GLP-1 receptor agonists offer potential concurrent hepatic and cardiovascular benefits
Cardiology Sys. Review
Novel pharmacotherapies like resmetirom and GLP-1 receptor agonists offer potential concurrent hepatic and cardiovascular benefits New Medications Show Potential to Treat Liver and Heart Disease
This systematic review examines the epidemiological links and shared pathophysiological mechanisms between metabolic dysfunction-associated …
Newer drugs like resmetirom and GLP-1 receptor agonists may offer dual benefits for patients with both liver and heart conditions.
Frontiers Jul 27, 2026
Intensive CV management reduces cIMT progression in RA patients without hepatic steatosis
Gastroenterology RCT
Intensive CV management reduces cIMT progression in RA patients without hepatic steatosis Liver health impacts heart risk management in rheumatoid arthritis
This post-hoc analysis of a randomized controlled trial involving 236 patients with rheumatoid arthritis evaluated intensive cardiovascular …
Patients with liver fat and rheumatoid arthritis show worse heart markers, but intensive care only slowed artery thickening for those withou…
Jul 25, 2026
Dapagliflozin plus pioglitazone reduces HbA1c by 0.49% and improves liver fat content in T2DM
Diabetes & Endocrinology Meta-analysis
Dapagliflozin plus pioglitazone reduces HbA1c by 0.49% and improves liver fat content in T2DM Combination Therapy Shows Promise for Diabetes and Liver Health
This systematic review and meta-analysis of 1411 patients found that dapagliflozin plus pioglitazone significantly improved glycemic control…
A combination of two medications may improve blood sugar levels and reduce liver fat in adults living with type 2 diabetes.
Frontiers Jul 21, 2026
Unified cardiometabolic disease framework links T2DM, ASCVD, HFpEF, MASLD, hypertension, and CKD via shared pathophysiology
Cardiology Guideline
Unified cardiometabolic disease framework links T2DM, ASCVD, HFpEF, MASLD, hypertension, and CKD via shared pathophysiology New Framework Links Heart and Kidney Health in Diabetes
This guideline provides a narrative review of the unified cardiometabolic disease (UCD) continuum. It argues that conditions like T2DM, ASCV…
Experts suggest that diabetes, heart failure, and kidney disease may share a single underlying cause rather than being separate conditions.
Frontiers Jul 19, 2026
Metabolic Dysfunction-Associated Steatotic Liver Disease prevalence reaches 56.9% among diabetic adults in India
Diabetes & Endocrinology Meta-analysis
Metabolic Dysfunction-Associated Steatotic Liver Disease prevalence reaches 56.9% among diabetic adults in India More than half of Indian adults with Type 2 Diabetes have liver disease
This systematic review and meta-analysis of 18 studies found a pooled MASLD prevalence of 56.9% among adult patients with Type 2 Diabetes Me…
Over half of adults in India with Type 2 Diabetes also have a fatty liver condition, highlighting a major link between these two health issu…
Jul 4, 2026
Citrus grandis Tomentosa flavonoids ameliorate hepatic steatosis and inflammatory responses in experimental MASLD models
Drug Pipeline Sys. Review
Citrus grandis Tomentosa flavonoids ameliorate hepatic steatosis and inflammatory responses in experimental MASLD models Citrus flavonoids show potential in treating fatty liver disease
This scoping review synthesizes preclinical data on the efficacy of Citrus grandis Tomentosa (CGT) flavonoids in metabolic dysfunction-assoc…
New research suggests specific citrus compounds may reduce inflammation and fat buildup in the liver, offering a possible path for future tr…
Frontiers Jun 24, 2026
Supervised structured exercise improves cardiorespiratory fitness in adults with MASLD by 3.52 mL/kg/min
Pulmonology & Critical Care Meta-analysis
Supervised structured exercise improves cardiorespiratory fitness in adults with MASLD by 3.52 mL/kg/min Supervised Exercise Improves Heart Fitness in MASLD Patients
This systematic review and dose-response meta-analysis of RCTs indicates that supervised structured exercise significantly improves cardiore…
New research shows that supervised, structured exercise significantly improves heart and lung fitness for adults living with MASLD.
Frontiers Jun 20, 2026
Lower liver-expressed TRIB1AL levels are associated with reduced liver fat and cardiovascular risk
Gastroenterology Meta-analysis
Lower liver-expressed TRIB1AL levels are associated with reduced liver fat and cardiovascular risk Genetic research identifies a new target for fatty liver disease
This meta-analysis examines the role of long noncoding RNA TRIB1AL in metabolic dysfunction-associated steatotic liver disease (MASLD). The …
Researchers identified a specific gene, TRIB1AL, that could be a key target for treating fatty liver and heart health issues.
Jun 17, 2026
Circular RNAs regulate hepatic lipid metabolism in NAFLD and MASLD via key signaling pathways
Genetics & Precision Medicine Sys. Review
Circular RNAs regulate hepatic lipid metabolism in NAFLD and MASLD via key signaling pathways Circular RNAs May Offer New Paths for Fatty Liver Disease
This systematic review synthesizes evidence on circular RNAs (circRNAs) in non-alcoholic fatty liver disease (NAFLD) and metabolic dysfuncti…
New research explores how circular RNAs could serve as important tools for diagnosing and treating fatty liver diseases like NAFLD and MASLD…
Frontiers Jun 16, 2026
MTARC1 inhibition may reduce cirrhosis and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease
Diabetes & Endocrinology Meta-analysis
MTARC1 inhibition may reduce cirrhosis and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease Blocking a liver protein could lower risks for fatty liver disease patients
This meta-analysis of data from the Quebec Obesity Biobank used integrated proteogenomic analysis and Mendelian randomization to assess caus…
A massive analysis suggests blocking a specific liver protein might reduce risks for fatty liver disease, cirrhosis, and cancer while improv…
medRxiv Jun 6, 2026
IGFBPs show dual roles in metabolic dysfunction-associated steatotic liver disease progression
Diabetes & Endocrinology Sys. Review
IGFBPs show dual roles in metabolic dysfunction-associated steatotic liver disease progression IGFBP proteins play opposite roles in liver disease progression
This narrative review synthesizes evidence on insulin-like growth factor-binding proteins (IGFBPs) in metabolic dysfunction-associated steat…
A review shows specific IGFBP proteins can protect the liver or drive damage depending on the stage of disease and which protein is involved…
Frontiers Jun 5, 2026

Questions about Metabolic Dysfunction-Associated Steatohepatitis

Can machine learning diagnose metabolic dysfunction-associated steatohepatitis and fibrosis?

Yes, machine learning models show good accuracy for diagnosing MASH and fibrosis, with pooled AUROCs around 0.83-0.84, but they are not yet ready to replace liver biopsy in clinical practice.

Full answer →
Which drugs work best for non-cirrhotic metabolic dysfunction-associated steatohepatitis?

For non-cirrhotic MASH, drugs targeting metabolism and insulin sensitivity (e.g., tirzepatide, semaglutide) work best, but lifestyle changes and weight loss are foundational.

Full answer →
Can lowering triglycerides help treat metabolic dysfunction-associated steatohepatitis?

Yes, lowering triglycerides may help treat MASH by reducing liver fat and improving inflammation, but more research is needed to confirm long-term benefits.

Full answer →

All Metabolic Dysfunction-Associated Steatohepatitis Articles